Wilex and ArcherDx deals see IVD consolidation continue
This article was originally published in Clinica
Executive Summary
Two acquisitions in the in vitro diagnostics field have highlighted the trend for increasing consolidation in the sector, and the medtech industry in general. The first is Nuclea Biotechnologies’ agreed purchase of troubled German biopharma firm Wilex’s US subsidiary, which specializes in companion diagnostics; while the second involves Enzymatics’ buy of next-generation sequencing specialist ArcherDx.